Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis{A figure is presented}

Gastrointestinal Endoscopy

Volumn 65, Issue 7, 2007, Pages 960-968

  Das, Ananya ^a   Singh, Pankaj ^a   Sivak Jr , Michael V ^a   Chak, Amitabh ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EVALUATION; HIGH RISK POPULATION; HUMAN; MEDICARE; PANCREAS STENT; PANCREATITIS; PRIORITY JOURNAL; REIMBURSEMENT; RISK REDUCTION; STENT;

ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; COST-BENEFIT ANALYSIS; DECISION MAKING; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MONTE CARLO METHOD; PANCREATIC DUCTS; PANCREATITIS; PROGNOSIS; PROSTHESIS IMPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPHINCTER OF ODDI DYSFUNCTION; STENTS;

EID: 34248661002     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2006.07.031     Document Type: Article

References (39)

1. Freeman M.L., and Guda N.M. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59 (2004) 845-864
2. Sherman S., Ruffolo T.A., Hawes R.H., et al. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 101 (1991) 1068-1075
3. Tarnasky P.R., Palesch Y.Y., Cunningham J.T., et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 115 (1998) 1518-1524
4. Smithline A., Silverman W., Rogers D., et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 39 (1993) 652-657
5. Fazel A., Quadri A., Catalano M.F., et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 57 (2003) 291-294
6. Aizawa T., and Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 54 (2001) 209-213
7. Fogel E.L., Eversman D., Jamidar P., et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 34 (2002) 280-285
8. Elton E., Howell D.A., Parsons W.G., et al. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc 47 (1998) 240-249
9. Norton I.D., Gostout C.J., Baron T.H., et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 56 (2002) 239-243
10. Catalano M.F., Linder J.D., Chak A., et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 59 (2004) 225-232
11. Freeman M.L., Overby C., and Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 5 (2004) 8-14
12. Vandervoort J., Soetikno R.M., Montes H., et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc 49 (1999) 322-327
13. Singh P., Das A., Isenberg G., et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis: a meta-analysis of controlled trials. Gastrointest Endosc 60 (2004) 544-550
14. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
15. Freeman M.L., DiSario J.A., Nelson D.B., et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54 (2001) 425-434
16. Masci E., Mariani A., Curioni S., et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 35 (2003) 830-834
17. Vandervoort J., Soetikno R.M., Tham T.C., et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 56 (2002) 652-656
18. Arnold J.C., Benz C., Martin W.R., et al. Endoscopic papillary balloon dilation vs. sphincterotomy for removal of common bile duct stones: a prospective randomized pilot study. Endoscopy 33 (2001) 563-567
19. Cotton P.B., Lehman G., Vennes J., et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 37 (1991) 383-393
20. HCUPnet. Healthcare cost and utilization project. Rockville (MD): Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/HCUPnet/. Accessed January 5, 2006.
21. National Center for Health Statistics. Life table for the total population: United States 2002. Nat Vital Stat Rep 53 (2004) 25-26
22. Beck J.R., Pauker S.G., Gottleib J.E., et al. A convenient approximation of the life expectancy (the DEALE). II. Use in medical decision making. Am J Med 73 (1982) 889-897
23. Naglie G., Krahn M.D., Naimark D., et al. Primer on medical decision analysis: estimating probabilities and utilities. Med Decis Making 17 (1997) 136-141
24. Buchbinder R., and Detsky A.S. Management of suspected giant cell arteritis: a decision analysis. J Rheumatol 19 (1992) 1220-1228
25. Gould M.K., Dembitzer A.D., Sanders G.D., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130 (1999) 789-799
26. Auerbach A.D., Sanders G.D., and Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 116 (2004) 816-828
27. Aujesky D., Smith K.J., and Roberts M.S. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 118 (2005) 625-635
28. Aujesky D., Smith K.J., Cornuz J., et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 128 (2005) 1601-1610
29. Doubilet P., Begg C.B., Weinstein M.C., et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 5 (1985) 157-177
30. Stinnett A.A., and Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18 Suppl 2 (1998) S68-S80
31. Heitjan D.F. Fieller's method and net health benefit. Health Econ 9 (2000) 327-335
32. Harewood G.C., Baron T.H., LeRoy A.J., et al. Cost-effectiveness analysis of alternate strategies for palliation of distal biliary obstruction after a failed cannulation attempt. Am J Gastroenterol 97 (2002) 1701-1707
33. Johanson J.F., Schmalz M.J., and Geenen J.E. Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc 38 (1992) 341-346
34. Smith M.T., Sherman S., Ikenberry S.O., et al. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 44 (1996) 268-275
35. Angus D.C., Barnato A.E., Linde-Zwirble W.T., et al. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med 32 (2004) 638-643
36. Pande H., and Thuluvath P.J. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 63 (2003) 1799-1812
37. Freeman M.L. Role of pancreatic stents in prevention of post-ERCP pancreatitis. JOP 5 (2004) 322-327
38. Proposed CY2005 hospital outpatient prospective payment system: addendum A. Available at: http://www.cms.hhs.gov/providers/hopps/fr2005.asp. Accessed October 4, 2006.
39. Harewood G.C., and Baron T.H. Cost analysis of magnetic resonance cholangiography in the management of inoperable hilar biliary obstruction. Am J Gastroenterol 97 (2002) 1152-1158